Dexilant

Basic Dexilant information

• INN (international nonproprietary name): Dexlansoprazole
• Brand name: Dexilant
• ATC code: A02BC06
• Forms and dosages: delayed‑release capsules, 30 mg and 60 mg, in blister packs or bottles
• Manufacturer: Takeda Pharmaceuticals
• Registration status in the United Kingdom: not licensed in the UK
• OTC / Rx classification: prescription only (Rx)

Legal status and availability in the UK

In our online pharmacy, Dexilant is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.

Clinical effectiveness in the UK

Does dexlansoprazole offer a clear clinical advantage?

Dexlansoprazole is used for erosive oesophagitis and symptomatic gastro‑oesophageal reflux disease where once‑daily dosing and nocturnal symptom relief matter to patients.

Symptom improvement is similar to other PPIs, with potential adherence benefits because dosing is less tied to meals.

It is generally reserved for patients who do not respond to or do not tolerate first‑line PPIs such as omeprazole or lansoprazole.

It may be chosen for patients with prominent nocturnal reflux or erratic meal patterns.

Treatment outcomes commonly include healing at eight weeks for erosive disease and relapse rates during maintenance up to six months.

Indications and expanded uses

What is dexlansoprazole used for?

Dexlansoprazole is used for healing erosive oesophagitis, maintenance of healed disease and symptomatic reflux disease (GORD), including in adolescents aged 12 and over.

Other uses can include chronic dyspepsia, adjunctive acid suppression in Barrett’s oesophagus surveillance and short‑term NSAID‑associated dyspepsia.

Prescribers must exclude alarm features for gastric malignancy before beginning long‑term PPI therapy to avoid masking serious diagnoses.

In the UK, dexlansoprazole is a prescription‑only medicine and is not licensed by the MHRA.

• Main uses: healing of erosive oesophagitis.
• Main uses: maintenance therapy to prevent relapse.
• Main uses: symptomatic GORD in adults and adolescents 12+.
• Other uses: Barrett’s surveillance adjunct.
• Other uses: chronic dyspepsia management.

Decision flow for escalation: If first‑line PPI (omeprazole/lansoprazole) fails or is not tolerated, review adherence and interactions, consider endoscopy if alarm features, then consider switching to dexlansoprazole for nocturnal symptoms or dosing flexibility.

Composition and brand landscape

What is in each capsule and which brands might a pharmacist see on dispensary lists?

Active ingredient: dexlansoprazole (international nonproprietary name).

Original manufacturer: Takeda Pharmaceuticals.

Dosage forms: delayed‑release capsules of 30 mg and 60 mg, supplied in blister packs or bottles.

ATC classification: A02BC06 — proton pump inhibitors.

• INN: Dexlansoprazole.
• ATC code: A02BC06.
• Dual delayed‑release definition: Two staggered releases in the GI tract to provide more consistent acid suppression with less meal timing dependence.

Contraindications and special precautions

Which patients should not take dexlansoprazole and who needs closer monitoring?

Absolute contraindications include hypersensitivity to dexlansoprazole or other PPIs and co‑administration with rilpivirine‑containing products.

Severe acute hepatic impairment is a contraindication, and moderate hepatic impairment requires the lowest effective dose or avoidance in severe cases.

Cautions reflect known PPI class risks such as bone fracture risk, hypomagnesaemia, reduced vitamin B12 absorption, and possible increased Clostridioides difficile risk in prolonged use.

High‑risk groups include the elderly due to polypharmacy and fracture risk, pregnant or breastfeeding patients where use should be clearly indicated, patients with significant liver disease, and those on interacting medicines.

• Contraindication: co‑administration with rilpivirine.
• Contraindication: acute severe hepatic impairment.
• Monitoring checklist: magnesium levels for long‑term users.
• Monitoring checklist: consider vitamin B12 and bone health in prolonged therapy.

Driving and machinery: no routine restriction, but advise patients to avoid driving if they experience dizziness or drowsiness.

Dosage guidelines

How should dexlansoprazole be dosed for different indications and populations?

Standard dosing: erosive oesophagitis healing — 60 mg once daily for up to eight weeks.

Maintenance of healed disease: 30 mg once daily for up to six months.

Symptomatic GORD: 30 mg once daily for up to four weeks.

Paediatric use: from age 12 years with the same dosing as adults.

• Elderly: No routine adjustment but monitor for sensitivity.
• Renal impairment: No dosage adjustment required.
• Hepatic impairment: Mild — no change; Moderate — use lowest effective dose; Severe — not recommended.

Missed dose advice: take as soon as remembered unless close to next dose; do not double dose.

Overdose: seek emergency medical care; supportive treatment only.

Interactions overview

What drugs should pharmacists check before dispensing dexlansoprazole?

Dexlansoprazole’s dual delayed‑release technology reduces meal timing constraints but drug interactions mirror PPI class concerns.

Severe interaction: avoid co‑administration with rilpivirine‑containing products.

Clinically relevant interactions include reduced absorption of drugs that require gastric acidity, such as atazanavir, potential altered antiplatelet effect with clopidogrel, and possible effects on warfarin pharmacokinetics.

Monitoring steps: check INR for patients on warfarin, review antiviral regimens, and assess need for alternative antiplatelet strategies if concerned.

Comparable medicines and prescriber preferences

When should a clinician stick with omeprazole or switch to dexlansoprazole?

First‑line options on the NHS remain omeprazole, lansoprazole and esomeprazole because of their well‑established use.

Dexlansoprazole is considered when specific clinical reasons apply such as the need for stable night‑time acid control or less strict meal timing.

Comparators include omeprazole (widely available), esomeprazole (higher potency debated), pantoprazole (fewer CYP interactions, used in hospitals) and lansoprazole (the parent racemate).

• Pros for dexlansoprazole: dosing flexibility, stable acid suppression, use from 12 years.
• Cons for dexlansoprazole: not licensed in the UK; formulary restrictions.

Checklist for switching: confirm adherence, review interactions, assess nocturnal symptoms and consider formulary rules before switching.

Frequently asked questions

Can I buy Dexilant over the counter?

No, dexlansoprazole is a prescription‑only medicine in the UK; speak to your GP or pharmacist for alternatives and assessment.

How long until I feel better after starting dexlansoprazole?

Many patients notice symptom relief within days, but healing for erosive disease is typically assessed at up to eight weeks on the 60 mg regimen.

Is dexlansoprazole safe for long‑term use?

Long‑term use carries class‑related risks; use the lowest effective dose and monitor magnesium, vitamin B12 and bone health where indicated.

What should I do if I miss a dose?

Take the missed dose as soon as you remember unless the next dose is due, and do not double up doses.

For reporting suspected adverse reactions, patients and professionals can use the MHRA Yellow Card system.

Guidelines for proper use: pharmacist counselling and NHS advice

What should pharmacists cover when handing out dexlansoprazole?

Confirm the indication and review current acid suppression use and adherence.

Check for interacting medicines such as rilpivirine, certain antivirals, clopidogrel and warfarin.

Advise patients that capsules are delayed‑release and can be taken without regard to meals, which helps shift‑workers and those with irregular eating patterns.

Storage advice: keep below 30°c in a dry place and retain in original packaging.

• Pharmacist checklist: verify indication, review interactions, set expectations for symptom timeline.
• Monitoring tests: serum magnesium for long‑term users, consider vitamin B12 if symptoms of deficiency, bone health review in high‑risk patients.
• Patient leaflet highlights: common side‑effects, missed dose advice, when to seek GP review.

Encourage use of the NHS App, GP online services or local pharmacy review clinics for repeat prescriptions and medication reviews.

Delivery across the United Kingdom